Lowest-Rated Stocks NASDAQ:ALLK Allakos Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $3.32 -0.11 (-3.21%) (As of 06/27/2022 10:57 AM ET) Add Compare Share Today's Range$3.22▼$3.4650-Day Range$2.60▼$4.8852-Week Range$2.54▼$11.73Volume42,472 shsAverage Volume1.48 million shsMarket Capitalization$181.86 millionP/E RatioN/ADividend YieldN/APrice Target$68.42 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allakos and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Stock Forecast (MarketRank)Overall MarketRank™2.33 out of 5 starsMedical Sector257th out of 1,411 stocksPharmaceutical Preparations Industry101st out of 672 stocksAnalyst Opinion: 3.1Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 - 3.1 Analyst's Opinion Consensus RatingAllakos has received a consensus rating of Hold. The company's average rating score is 2.10, and is based on 2 buy ratings, 7 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $68.42, Allakos has a forecasted upside of 1,894.8% from its current price of $3.43.Amount of Analyst CoverageAllakos has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Community Rank Outperform VotesAllakos has received 170 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAllakos has received 117 “underperform” votes. (Add your “underperform” vote.)Community SentimentAllakos has received 59.23% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Allakos and other stocks. Vote “Outperform” if you believe ALLK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ALLK will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAllakos does not currently pay a dividend.Dividend GrowthAllakos does not have a long track record of dividend growth. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allakos insiders have not sold or bought any company stock.Percentage Held by Insiders33.25% of the stock of Allakos is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions61.07% of the stock of Allakos is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Allakos are expected to grow in the coming year, from ($5.68) to ($3.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allakos is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allakos is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllakos has a P/B Ratio of 0.42. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allakos (NASDAQ:ALLK)Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis; a Phase II/III study for eosinophilic esophagitis; and a Phase II clinical study to atopic dermatitis and chronic spontaneous urticaria. It is also developing lirentelimab (AK002) for the treatment of mast cell gastrointestinal disease, chronic urticaria, severe allergic conjunctivitis, and indolent systemic mastocytosis; and AK006 to treat allergic and inflammatory diseases. The company was incorporated in 2012 and is headquartered in Redwood City, California.Read More ALLK Stock News HeadlinesJune 17, 2022 | benzinga.comDow Jones Turns Lower; Revlon Shares Jump - Benzinga - BenzingaJune 16, 2022 | benzinga.comONGOING INVESTIGATION ALERT: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties - BenzingaJune 13, 2022 | benzinga.comINVESTIGATION NOTICE: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Mana - BenzingaJune 10, 2022 | benzinga.comINVESTIGATION REMINDER: The Schall Law Firm Announces Investigation of Breaches of Fiduciary Duties by Ma - BenzingaJune 9, 2022 | americanbankingnews.comCantor Fitzgerald Weighs in on Allakos Inc.'s FY2023 Earnings (NASDAQ:ALLK)June 8, 2022 | finance.yahoo.comAqualung Therapeutics Appoints Two New Board Directors; Will Attend June 22 Bio Meeting in San Diego - Yahoo FinanceMay 27, 2022 | bizjournals.comAfter a record-breaking decade, biotech is discovering what hard times feel like - San Francisco Business Times - The Business JournalsMay 24, 2022 | benzinga.comGoldman Sachs Maintains Neutral on Allakos, Lowers Price Target to $4 - Benzinga - BenzingaMay 18, 2022 | streetinsider.comAllakos Inc. (ALLK) PT Lowered to $10 at Cantor Fitzgerald, But BUY Rating Maintained, "Still Believe that the Market Opportunity for lirentelimab is Underappreciated" - StreetInsider.comMay 13, 2022 | markets.businessinsider.comWhat 4 Analyst Ratings Have To Say About AllakosMay 12, 2022 | benzinga.comWhat 4 Analyst Ratings Have To Say About Allakos - Benzinga - BenzingaMay 12, 2022 | benzinga.comSVB Leerink Maintains Market Perform on Allakos, Lowers Price Target to $12 - Benzinga - BenzingaMay 10, 2022 | benzinga.comMorgan Stanley Maintains Equal-Weight on Allakos, Lowers Price Target to $6 - Benzinga - BenzingaSee More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLK CUSIPN/A CIK1564824 Webwww.allakos.com Phone(650) 597-5002FaxN/AEmployees192Year FoundedN/ACompany Calendar Last Earnings5/06/2022Today6/27/2022Next Earnings (Estimated)8/08/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$68.42 High Stock Price Forecast$155.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+1,960.9%Consensus RatingHold Rating Score (0-4)2.1 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($7.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-269.86 million Net MarginsN/A Pretax MarginN/A Return on Equity-80.07% Return on Assets-68.14% Debt Debt-to-Equity RatioN/A Current Ratio6.87 Quick Ratio6.87 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.20 per share Price / Book0.40Miscellaneous Outstanding Shares54,777,000Free Float36,564,000Market Cap$181.86 million OptionableNot Optionable Beta0.98 Allakos Frequently Asked Questions Should I buy or sell Allakos stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allakos in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Allakos stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALLK, but not buy additional shares or sell existing shares. View analyst ratings for Allakos or view top-rated stocks. What is Allakos' stock price forecast for 2022? 10 Wall Street analysts have issued 1 year target prices for Allakos' shares. Their ALLK stock forecasts range from $13.00 to $155.00. On average, they anticipate Allakos' share price to reach $68.42 in the next twelve months. This suggests a possible upside of 1,960.9% from the stock's current price. View analysts' price targets for Allakos or view top-rated stocks among Wall Street analysts. How has Allakos' stock price performed in 2022? Allakos' stock was trading at $9.79 at the start of the year. Since then, ALLK stock has decreased by 66.1% and is now trading at $3.32. View the best growth stocks for 2022 here. When is Allakos' next earnings date? Allakos is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022. View our earnings forecast for Allakos. How were Allakos' earnings last quarter? Allakos Inc. (NASDAQ:ALLK) released its quarterly earnings data on Friday, May, 6th. The company reported ($3.60) earnings per share for the quarter, missing the consensus estimate of ($1.71) by $1.89. View Allakos' earnings history. Who are Allakos' key executives? Allakos' management team includes the following people: Dr. Robert Alexander Ph.D., CEO & Director (Age 52, Pay $1.39M)Dr. Adam L. Tomasi Ph.D., Pres & COO (Age 52, Pay $1.06M)Mr. Baird Radford III, Chief Financial OfficerMr. Mark Asbury J.D., Exec. Officer (Age 59, Pay $701.69k)Dr. Ruby Casareno Ph.D., Sr. VP of Technical OperationsMeg Fitzgerald, Sr. VP, Gen. Counsel, Sec. and Chief Compliance OfficerDr. Sally D. Bolmer, Sr. VP of Regulatory Affairs & Drug Devel.Dr. Henrik Sandvad Rasmussen, Strategic Advisor (Age 63)Dr. Craig Paterson M.D., Chief Medical OfficerBrad Youngblood, Head of Research Who are some of Allakos' key competitors? Some companies that are related to Allakos include Kiniksa Pharmaceuticals (KNSA), MorphoSys (MOR), CinCor Pharma (CINC), Avidity Biosciences (RNA), Catalyst Pharmaceuticals (CPRX), Erasca (ERAS), Northwest Biotherapeutics (NWBO), Theravance Biopharma (TBPH), Ventyx Biosciences (VTYX), Emisphere Technologies (EMIS), Keros Therapeutics (KROS), Nuvalent (NUVL), Zealand Pharma A/S (ZEAL), Organogenesis (ORGO) and POINT Biopharma Global (PNT). View all of ALLK's competitors. What other stocks do shareholders of Allakos own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allakos investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Pfizer (PFE), Agios Pharmaceuticals (AGIO), Biohaven Pharmaceutical (BHVN), bluebird bio (BLUE), Eastman Chemical (EMN), Heron Therapeutics (HRTX), TG Therapeutics (TGTX) and Arbutus Biopharma (ABUS). When did Allakos IPO? (ALLK) raised $96 million in an IPO on Thursday, July 19th 2018. The company issued 6,000,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Jefferies acted as the underwriters for the IPO and William Blair was co-manager. What is Allakos' stock symbol? Allakos trades on the NASDAQ under the ticker symbol "ALLK." Who are Allakos' major shareholders? Allakos' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.32%), Vanguard Group Inc. (4.84%), Goldman Sachs Group Inc. (1.84%), State Street Corp (1.43%), PDT Partners LLC (1.21%) and Clearline Capital LP (0.98%). Company insiders that own Allakos stock include Adam Tomasi, Daniel Janney, Guy P Nohra, Henrik S Md Rasmussen, John P Mckearn, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More and Steven P James. View institutional ownership trends for Allakos. Which major investors are selling Allakos stock? ALLK stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., State Street Corp, Simplex Trading LLC, Group One Trading L.P., Bank of America Corp DE, Citigroup Inc., RBF Capital LLC, and Cutler Group LP. Company insiders that have sold Allakos company stock in the last two years include Adam Tomasi, Daniel Janney, Henrik S Md Rasmussen, Paul Edward Walker, Peter A Hudson, Robert Alexander, Robert J More, and Steven P James. View insider buying and selling activity for Allakos or view top insider-selling stocks. Which major investors are buying Allakos stock? ALLK stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., PDT Partners LLC, Clearline Capital LP, JPMorgan Chase & Co., Acadian Asset Management LLC, Healthcare of Ontario Pension Plan Trust Fund, BlackRock Inc., and Renaissance Technologies LLC. View insider buying and selling activity for Allakos or or view top insider-buying stocks. How do I buy shares of Allakos? Shares of ALLK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allakos' stock price today? One share of ALLK stock can currently be purchased for approximately $3.32. How much money does Allakos make? Allakos (NASDAQ:ALLK) has a market capitalization of $181.86 million. The company earns $-269.86 million in net income (profit) each year or ($7.56) on an earnings per share basis. How many employees does Allakos have? Allakos employs 192 workers across the globe. How can I contact Allakos? Allakos' mailing address is 975 ISLAND DRIVE SUITE 201, REDWOOD CITY CA, 94065. The official website for Allakos is www.allakos.com. The company can be reached via phone at (650) 597-5002 or via email at [email protected]. This page (NASDAQ:ALLK) was last updated on 6/27/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here